Puma Biotechnology, Inc. (NYSE:PBYI) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $34.25, up from yesterday’s close by -2.84%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.
It’s important to get a feel for how any stock is actually valued on the market based on its core numbers. Puma Biotechnology, Inc. (PBYI) currently trades with a market capitalization of $1.30B.
The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For PBYI, the company currently has $108.93M of cash on the books, which is offset by $0.00 current liabilities. You can get a sense of how sustainable that is by a levered free cash flow of $-51.76M over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of -2.02 on a per share basis this quarter. Perhaps, that suggests something about why 95.30% of the outstanding share supply is held by institutional investors.
No analysis is ever complete without a thorough survey of a stock’s technical behavior. Looking at the stock’s movement on the chart, Puma Biotechnology, Inc. recorded a 52-week high of 73.27. It is now trading 38.67 off that level. The stock is trading 36.72 its 50-day moving average by 2.12. The stock carved out a 52-week low down at 19.74.
In recent action, Puma Biotechnology, Inc. (PBYI) has made a move of -6.04% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 51.26, and it’s gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 23.79M with 31.45% sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of PBYI.